| Document |
Document Title |
|
WO/2024/101047A1 |
According to the present invention, a graft rejection reaction is reduced, and extracellular vesicles derived from cells having physiological activity against at least one disease among kidney diseases, peripheral arterial disease (PAD),...
|
|
WO/2024/102706A1 |
Provided herein are methods of treating, preventing, managing, and/or ameliorating androgen receptor mediated diseases with a combination of 3-((3- aminophenyl)amino)piperidine-2, 6-dione compounds and a second agent.
|
|
WO/2024/102734A1 |
The present disclosure provides methods for treating childhood-onset idiopathic nephrotic syndrome (INS), or reducing risk and/or frequency of relapse from childhood-onset INS, in an individual that is greater than or equal to 2 years of...
|
|
WO/2024/102026A1 |
This invention relates to organic chemistry, pharmacology, medicine, namely the invention relates to compounds for use in inhibiting the activity of human cytochrome 11B2 (CYP11B2) and their use in the treatment and/or prevention of vari...
|
|
WO/2024/099272A1 |
A method for treating IgA nephropathy and a pharmaceutical composition comprising an endothelin receptor antagonist and a glucocorticoid.
|
|
WO/2024/101209A1 |
The purpose of the present invention is to provide: a composition for preventing the deterioration in kidney functions or improving kidney functions; and a method for preventing the deterioration in kidney functions or improving kidney f...
|
|
WO/2024/099361A1 |
Disclosed in the present invention are a crystal form of an alkyl carboxylic acid compound and the use thereof. Specifically disclosed are a crystal form of the compound as represented by formula (I) and the use thereof.
|
|
WO/2024/101159A1 |
A pharmaceutical composition comprising nano-fibers and/or nano-flakes of a material represented by formula: MQaOb (in the formula, M represents at least one element selected from the group consisting of group 3, 4, 5, 6 and 7 elements, ...
|
|
WO/2024/100453A1 |
Provided herein are methods of treating lupus nephritis using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of lupus nephritis and for use in the manufacture of a medicam...
|
|
WO/2024/100455A1 |
Provided herein are methods of treating primary membranous nephropathy using an effective amount of a human neonatal Fc receptor (FcRn) antagonist. FcRn antagonists for use in the treatment of primary membranous nephropathy and for use i...
|
|
WO/2024/099429A1 |
A compound of formula (I) for regulating and controlling the activity of 15-PGDH, or a stereoisomer, tautomer or mixture thereof, or a pharmaceutical salt, solvate or prodrug thereof, a pharmaceutical composition containing same and the ...
|
|
WO/2024/101440A1 |
Provided is a compound represented by formula (1): [in the formula, the definitions for variables are as defined in the description] or a pharmaceutically acceptable salt thereof.
|
|
WO/2024/102886A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such comp...
|
|
WO/2024/102884A1 |
Disclosed are compounds of Formulas (I): (I) or a salt thereof, wherein L, R1, R2, R3, and R4 are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such c...
|
|
WO/2024/102913A1 |
The present disclosure provides methods of treating a subject having a kidney disease or preventing a subject from developing a kidney disease by administering an Angiopoietin Like 3 (ANGPTL3) inhibitor and a Solute Carrier Family 5 Memb...
|
|
WO/2024/095992A1 |
The present invention addresses the problem of providing a novel means for suppressing renal hypofunction, the means being capable of fundamentally improving diseases associated with renal hypofunction, including chronic kidney disease (...
|
|
WO/2024/097163A1 |
Methods of treating paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, or idiopathic immune complex-mediated glomerulonephritis using MASP-3 serine protease inhibitors are provided. In some embodiments, the MASP-3 serine p...
|
|
WO/2024/097138A1 |
Alternative splicing events in genes can lead to non-productive mRNA transcripts which in turn can lead to aberrant or reduced protein expression, and therapeutic agents which can target the alternative splicing events in the genes can m...
|
|
WO/2024/097620A1 |
Compositions and methods comprising antibodies that bind to integrin α3β1 are provided.
|
|
WO/2024/097861A1 |
Provided herein are methods of ameliorating a disease or disorder associated with dysregulation of the alternative complement pathway by administering a Complement Factor B (CFB) specific inhibitor to a subject.
|
|
WO/2024/093944A1 |
The present invention relates to the field of pharmaceutical chemicals, and in particular, to a solid dispersion of a curcumin derivative C66, a method for preparing same, and use thereof. In the solid dispersion described by the present...
|
|
WO/2024/092040A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/088315A1 |
Provided here are methods of treating primary membranous nephropathy in a patient in need thereof, comprising administering to said patient a BTK inhibitor, e.g., (S) -7- (1-acryloylpiperidin-4-yl) -2- (4-phenoxyphenyl) -4, 5, 6, 7-tetra...
|
|
WO/2024/092037A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/091489A1 |
Provided are compounds of the Formula (I):; or pharmaceutically acceptable salts thereof, which can be useful for the inhibition of Drp 1 and in the treatment of a variety of Drp 1l mediated conditions or diseases.
|
|
WO/2024/092043A1 |
Provided herein are compounds that stabilize immunoglobulin light chains, and pharmaceutically acceptable derivatives thereof. Also provided are pharmaceutical compositions containing the compounds and methods of using the compounds for ...
|
|
WO/2024/091882A1 |
This patent document discloses novel compounds and methods of preventing or treating diseases or conditions related to Keapl-Nrf2interaction activity by use of the novel compounds. As direct inhibitors of Keapl-Nrf2 interaction, the comp...
|
|
WO/2024/092159A1 |
The present invention provides methods, systems, articles of manufacture, and kits related to treatment of muscle invasive bladder cancer with gemcitabine.
|
|
WO/2024/088175A1 |
Disclosed in the present disclosure are a gRNA targeting VEGFA, a gene editing system, and the use thereof. The gRNA in the present disclosure comprises a guide sequence which has at least 80% sequence identity to any one of SEQ ID NOs: ...
|
|
WO/2024/088307A1 |
Disclosed are a novel peptidyl nitrile compound and a use thereof, and specifically disclosed are a compound of formula (I) and/or a pharmaceutically acceptable salt thereof, a pharmaceutical composition comprising the compound and/or th...
|
|
WO/2024/092240A1 |
The present disclosure relates to the use of an endothelin receptor antagonist, or a pharmaceutically acceptable salt thereof, and isolated antibodies, including antigen-binding fragments thereof, which bind human APRIL for the treatment...
|
|
WO/2024/088364A1 |
The present disclosure relates to a pharmaceutical composition containing an isoquinolinone compound, and to a preparation method therefor. Specifically, the present disclosure provides a pharmaceutical composition containing 9,10-dimeth...
|
|
WO/2024/090521A1 |
Provided is a pharmaceutical composition for treating and/or preventing renal cystic ciliopathy, the composition containing a retinoic acid receptor (RAR) agonist.
|
|
WO/2024/087834A1 |
The present invention relates to a composition comprising a growth hormone fusion protein and a use thereof. The composition comprises: the growth hormone fusion protein and at least one of a buffering agent and a protective agent; a use...
|
|
WO/2024/088293A1 |
The present disclosure relates to a composition comprising an anti-MASP2 antibody, and the pharmaceutical use. Specifically, the present disclosure relates to a pharmaceutical composition comprising an anti-MASP2 antibody or an antigen-b...
|
|
WO/2024/085081A1 |
Provided is an antibody that specifically binds to the extracellular domain of human LPA1 but does not specifically bind to the extracellular domain of human LPA2 or the extracellular domain of human LPA3. The antibody preferably has act...
|
|
WO/2024/085166A1 |
The present invention addresses the problem of: providing an anti-CLDN4-anti-CD137 bispecific antibody to be used in combination with a PD-1 signal inhibitor for treatment of a cancer, or a pharmaceutical composition comprising said bisp...
|
|
WO/2024/082383A1 |
The present invention provides an anti-human interleukin 36 receptor (IL-36R) monoclonal antibody and a use thereof. The monoclonal antibody comprises three heavy chain complementarity determining regions CDR-H1, CDR-H2 and CDR-H3 and th...
|
|
WO/2024/083176A1 |
Disclosed are the uses of amniotic fluid in the preparation of a drug for treating and/or preventing macrophage-mediated diseases, a drug for treating and/or preventing type M1 macrophage-mediated diseases, a drug for treating and/or pre...
|
|
WO/2024/086240A1 |
Disclosed herein are compositions for supporting bladder health and/or treating, ameliorating, preventing, or reducing overactive bladder or the symptoms associated therewith. The compositions disclosed herein comprise a beta-adrenergic ...
|
|
WO/2024/086756A1 |
A method of treating, ameliorating, or preventing a condition characterized by one or both of reduced renal function and renal fibrosis is described, which includes interfering with one or both of an expression and an activity of a cadhe...
|
|
WO/2024/080441A1 |
The present invention provides: a Paracoccus aminovorans BM109 strain (accession number KCTC 15059BP), which is excellent for removing trimethylamine (TMA) or trimethylamine N-oxide (TMAO); and a pharmaceutical composition for preventing...
|
|
WO/2024/079471A1 |
A prebiotic oligosaccharide composition for use in reducing the level of ammonia. The composition comprises oligosaccharide compounds, for example galactooligosaccharide compounds, which includes: (a) at least 8 wt% Gal-(β1-3)-Gal-(β1-...
|
|
WO/2024/080323A1 |
Provided is a novel use of a composition that contains a prescribed sulfur-containing compound, a salt thereof, or both. The present invention is a sirtuin activator or expression enhancer, a NAD+ increasing agent, or a senescent cell in...
|
|
WO/2024/079324A1 |
The present invention relates to a composition for use in the treatment of a disease or disorder, wherein said disease or disorder is preferably a disease or disorder in which aldosterone overexposure contributes to the symptoms of said ...
|
|
WO/2024/077987A1 |
The present invention relates to the field of medicine. Specifically, disclosed is a PRDX1 IgG neutralizing antibody, which is a monoclonal neutralizing antibody against a PRDX1 protein or a polyclonal neutralizing antibody against the P...
|
|
WO/2024/079524A1 |
Provided herein are compositions and methods for treating kidney disease, for example diabetic kidney disease, using compositions comprising SDC2+ stromal stem cells.
|
|
WO/2024/077488A1 |
Use of a polygonum capitatum granular preparation in the preparation of drugs for clearing heat and promoting diuresis, inducing diuresis for treating stranguria, treating urinary tract infection or stones, treating pyelonephritis, detox...
|
|
WO/2024/077489A1 |
The use of a Polygonum capitatum Buch-Ham ex D. Don extract in the preparation of Relinqing granules for clearing heat and removing dampness, inducing diuresis for treating strangurtia, treating urinary system infections or stones, treat...
|
|
WO/2024/079331A1 |
The invention relates to the field of drug delivery for inflammatory diseases, more specifically inflammatory kidney, eye, lung, and intestinal diseases, and kidney, eye, lung and intestinal diseases in general.
|
